%0 Journal Article %A Alexei Vazquez %A Maximilian Staebler %A Alexander Khanin %A Daniel Lichte %A Eva Brucherseifer %T Estimating the super-spreading rate at workplaces using bluetooth technology %D 2021 %R 10.1101/2021.03.04.21252550 %J medRxiv %P 2021.03.04.21252550 %X Workplaces deploy internal guidelines to remain operational during the ongoing COVID-19 pandemic. It is challenging to assess whether those interventions will prevent super-spreading events, where an infected individual transmits the disease to 10 or more secondary cases. Here we provide a model of infectious disease at the level of a workplace to address that problem. We take as input proximity contact records based on bluetooth technology and the infectious disease parameters from the literature. Using proximity contact data for a case-study workplace and an infection transmission model, we estimate the SARS-CoV-2 transmission rate as 0.014 per proximity contact, going up to 0.041 for the SARS-CoV-2 B.1.1.7 variant first detected in the UK. Defining super-spreading as events with 10 or more secondary infections, we obtain a super-spreading event rate of 2.3 per 1000 imported SARS-CoV-2 cases, rising up to 13.7 for SARS-CoV-2 B.1.1.7. This methodology provides the means for workplaces to determine their internal super-spreading rate or other infection related risks.Competing Interest StatementES has indirect shares and convertible loans in Secufy GmbH.Funding StatementThis project was supported by DLR project ResTAT.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The DLR ethics office declared that the study is exempt from ethical oversight according to local legislation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData access is restricted due to intellectual property constraints. %U https://www.medrxiv.org/content/medrxiv/early/2021/03/08/2021.03.04.21252550.full.pdf